Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04100135 · ClinicalTrials.gov registry record · NA
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
A NA study, sponsored by W.L.Gore & Associates.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT04100135 is a NA study that was terminated before completion, run by W.L.Gore & Associates. The registered enrollment target is 7 participants.
The verdict
NCT04100135, a NA study, was terminated before completion, sponsored by W.L.Gore & Associates.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
Interventions
- DEVICE Actual device PFO closure
- DRUG Thienopyridine (clopidogrel or prasugrel)
- DEVICE Sham device PFO closure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-02-05 |
| Est. Completion | 2024-08-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04100135
The ClinicalTrials.gov registry entry for NCT04100135 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Actual device PFO closure is the first listed.
NCT04100135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04100135 about?
NCT04100135 is a clinical study titled "GORE® CARDIOFORM Septal Occluder Migraine Clinical Study". Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
What is the current status of trial NCT04100135?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2021-02-05. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT04100135?
The interventions under investigation include: Actual device PFO closure (DEVICE), Thienopyridine (clopidogrel or prasugrel) (DRUG), Sham device PFO closure (DEVICE).
Who is sponsoring clinical trial NCT04100135?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.